Resistance to 9-β-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: Implications for different sensitivities to nucleoside analogues

International Journal of Hematology

Volumn 81, Issue 5, 2005, Pages 405-412

  Yoshio, Nobuyuki ^a   Kawai, Yasukazu ^a   Hori, Hiroki ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

9 D Arabinofuranosyl 2 fluoroadenine; Cross resistance; dATP pool; Deoxycytidine kinase; L1210 leukemia cells

Indexed keywords

DEOXYADENOSINE DERIVATIVE; DEOXYADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE TRIPHOSPHATE; DNA; FLUDARABINE; HYDROXYUREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DNA BINDING; DRUG RESISTANCE; ENZYME MECHANISM; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION;

ANIMALS; BINDING, COMPETITIVE; BIOTRANSFORMATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTARABINE; DEOXYADENINE NUCLEOTIDES; DEOXYCYTOSINE NUCLEOTIDES; DNA; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HYDROXYUREA; MICE; NUCLEOSIDES; VIDARABINE;

EID: 21444440912     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05008     Document Type: Article

References (27)

1. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
2. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995;47:1072-1079.
3. Takagi K, Kawai Y, Yamauchi T, Ueda T. Inhibition of repair of carboplatin-induced DNA damage by 9-β-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes. Biochem Pharmacol. 2004;68:1757-1766.
4. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7:3580-3589.
5. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990;17:3-17.
6. Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106:78-85.
7. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: a mechanism for cytotoxicity. J Biol Chem. 1990;265:16617-16625.
8. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995;36:181-188.
9. White EL, Shaddix SC, Brockman RW, Bennett LL Jr. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D- arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. 1982;42:2260-2264.
10. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34:485-491.
11. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol. 1982;21:474-477.
12. Bai L, Yamaguchi M, Tatsumi M, Kon K, Brautigam M. Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-β-D-arabinofuranosyl-2-fluoroadenine. J Cancer Res Clin Oncol. 1998;124:367-373.
13. Månsson E, Spasokoukotskaja T, Sallstrom J, Eriksson S, Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res. 1999;59:5956-5963.
14. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991;142: 257-265.
15. Kawai Y, Ueda T, Nakamura T. Modulation of the effect of 1-β-D-arabinofuranosylcytosine by 6-mercaptopurine in L1210 cells. Jpn J Cancer Res. 1994;85:978-985.
16. Yamauchi T, Ueda T, Nakamura T. A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo. Cancer Res. 1996;56:1800-1804.
17. Yamauchi T, Ueda T. Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799:81-86.
18. Tahaka K, Yoshioka A, Tanaka S, Wataya Y. An improved method for the quantitative determination of deoxyribonucleoside triphosphates in cell extracts. Anal Biochem. 1984;139:35-41.
19. Sherman PA, Fyfe JA. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 1989;180:222-226.
20. Gao WY, Johns DG, Mitsuya H. Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2′,3′-dideoxynucleosides. Anal Biochem. 1994;222:116-122.
21. Rauscher F 3rd, Cadman E. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-β-D- arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res. 1983;43:2688-2693.
22. Månsson E, Flordal E, Liliemark J, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 2003;65:237-247.
23. Kawasaki H, Kuwabara H, Hori H, Higashigawa M, Ohkubo T, Sakurai M. Intracellular dCTP/ara-CTP ratio and the cytotoxic effect of ara-C. Cancer Invest. 1991;9:409-413.
24. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 1999;59:4204-4207.
25. Ullman B, Gudas LJ, Clift SM, Martin DW Jr. Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc Natl Acad Sci U S A. 1979;76:1074-1078.
26. Eriksson S, Gudas LJ, Ullman B, Clift SM, Martin DW Jr. Deoxy-ATP-resistant ribonucleotide reductase of mutant mouse lymphoma cells: evidence for heterozygosity for the protein M1 subunits. J Biol Chem. 1981;256:10184-10188.
27. Caras IW, Martin DW Jr. Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells. Mol Cell Biol. 1988;8: 2698-2704.